Dolpar

Dolpar may be available in the countries listed below.

Ingredient matches for Dolpar

Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Dolpar in the following countries:

• Spain

International Drug Name Search

Prednisolon-Rotexmedica

Prednisolon-Rotexmedica may be available in the countries listed below.

Ingredient matches for Prednisolon-Rotexmedica

Prednisolone

Prednisolone 21-acetate (a derivative of Prednisolone) is reported as an ingredient of Prednisolon-Rotexmedica in the following countries:

• Germany

International Drug Name Search

Acetylcystein Nycomed

Acetylcystein Nycomed may be available in the countries listed below.

Ingredient matches for Acetylcystein Nycomed

Acetylcysteine

Acetylcysteine is reported as an ingredient of Acetylcystein Nycomed in the following countries:

• Estonia


• Latvia

International Drug Name Search

Frakidex

Frakidex may be available in the countries listed below.

Ingredient matches for Frakidex

Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Frakidex in the following countries:

• Belgium


• France


• Switzerland

Framycetin

Framycetin sulfate (a derivative of Framycetin) is reported as an ingredient of Frakidex in the following countries:

• Belgium


• France


• Switzerland

International Drug Name Search

Fluoxetina Tuneluz

Fluoxetina Tuneluz may be available in the countries listed below.

Ingredient matches for Fluoxetina Tuneluz

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Tuneluz in the following countries:

• Portugal

International Drug Name Search

Salpad

Salpad may be available in the countries listed below.

Ingredient matches for Salpad

Salicylic Acid

Salicylic Acid is reported as an ingredient of Salpad in the following countries:

• Argentina

International Drug Name Search

RE-Nata 29 OB Prenatal Vitamin Tablets

Dosage Form: tablet
RE-Nata 29 OB Prenatal Vitamin Tablets

DESCRIPTION:

RE-Nata 29 OB Prenatal Vitamin Tablets are prescription prenatal vitamins.

INACTIVE INGREDIENTS:

RE-Nata 29 OB Prenatal Vitamins Tablets also contain carnauba wax, croscarmellose sodium, dicalcium phosphate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid, titanium dioxide.

INDICATIONS AND USAGE:

RE-Nata 29 OB Prenatal Vitamin Tablets are indicated to provide vitamin and mineral supplementation throughout pregnancy and during postnatal period for the lactating and non-lactating mother. It is also useful for improving the nutritional status prior to conception.


RE-Nata 29 OB Prenatal Vitamin Tablets contain 1 mg folic acid, which is very important in the development of the baby’s spinal column, especially during the first trimester. Women are advised to start taking folate supplementation several weeks before conception and to continue taking them through the first 12 weeks of pregnancy, or longer. It is recommended that all women of childbearing years take supplements containing folic acid.

CONTRAINDICATIONS:

RE-Nata 29 OB Prenatal Vitamin Tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. Folic acid (pteroylglutamic acid) is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. Iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia or cirrhosis of the liver.

WARNINGS:

Pernicious anemia should be ruled out before starting treatment. While folic acid corrects the hematological profile of pernicious anemia, it does not ameliorate the underlying neurologic involvement.

PRECAUTIONS:

General: Before prescribing to patients with kidney stones, the calcium content should be considered. Folic acid may partially correct the hematological damage due to deficiency of pernicious anemia, while the associated neurological damage progresses. In rare instances allergic sensitization has been reported following both oral and parenteral administration of folic acid.


Pediatric Use: Safety and effectiveness in children has not been established.

ADVERSE REACTIONS:

Allergic sensitivity reactions and gastrointestinal disturbances may occur. By taking RE-Nata 29 OB Prenatal Vitamin Tablets shortly after meals, G.I. disturbances may be controlled.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

DOSAGE AND ADMINISTRATION:

One tablet daily, or as directed by physician.

HOW SUPPLIED:

RE-Nata 29 OB Prenatal Vitamin Tablets are supplied as round, white tablets, debossed with “RE 394,” in bottles of 90 tablets (NDC # 68032-394-90). Dispense in a tight, light-resistant container with a child resistant closure as defined by the USP.

STORAGE:

Store at controlled room temperature 15°–30°C (59°–86°F). Protect from moisture and excessive heat.


KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.


Mfd. for:

River’s Edge Pharmaceuticals, LLC

Suwanee, GA 30024

Rev. 04/09 394-11

PACKAGING:

RE NATA OB   beta carotene, ascorbic acid, cholecalciferol, alpha-tocopherol, thiamine mononitrate, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, biotin, pantothenic acid, calcium carbonate, iron pentacarbonyl, potassium iodide, zinc oxide, cupric oxide, magnesium oxide  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 68032-394 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BETA CAROTENE (BETA CAROTENE) BETA CAROTENE 4000 [iU] ASCORBIC ACID (ASCORBIC ACID) ASCORBIC ACID 120 mg CHOLECALCIFEROL (CHOLECALCIFEROL) CHOLECALCIFEROL 400 [iU] ALPHA-TOCOPHEROL (ALPHA-TOCOPHEROL) ALPHA-TOCOPHEROL 30 [iU] THIAMINE MONONITRATE (THIAMINE) THIAMINE MONONITRATE 3 mg RIBOFLAVIN (RIBOFLAVIN) RIBOFLAVIN 3 mg NIACINAMIDE (NIACINAMIDE) NIACINAMIDE 20 mg PYRIDOXINE HYDROCHLORIDE (PYRIDOXINE) PYRIDOXINE HYDROCHLORIDE 3 mg FOLIC ACID (FOLIC ACID) FOLIC ACID 1 mg CYANOCOBALAMIN (CYANOCOBALAMIN) CYANOCOBALAMIN 8 ug BIOTIN (BIOTIN) BIOTIN 30 ug PANTOTHENIC ACID (PANTOTHENIC ACID) PANTOTHENIC ACID 7 mg CALCIUM CARBONATE (CALCIUM) CALCIUM CARBONATE 200 mg IRON PENTACARBONYL (IRON) IRON PENTACARBONYL 29 mg POTASSIUM IODIDE (POTASSIUM CATION) POTASSIUM IODIDE 150 ug ZINC OXIDE (ZINC) ZINC OXIDE 15 mg CUPRIC OXIDE (CUPRIC OXIDE) CUPRIC OXIDE 3 mg MAGNESIUM OXIDE (MAGNESIUM) MAGNESIUM OXIDE 100 mg

Inactive Ingredients Ingredient Name Strength CARNAUBA WAX   CROSCARMELLOSE SODIUM   ANHYDROUS DIBASIC CALCIUM PHOSPHATE   HYPROMELLOSES   MAGNESIUM STEARATE   CELLULOSE, MICROCRYSTALLINE   POLYETHYLENE GLYCOL   STEARIC ACID   TITANIUM DIOXIDE

Product Characteristics Color white Score no score Shape ROUND Size 8mm Flavor Imprint Code RE;394 Contains

Packaging # NDC Package Description Multilevel Packaging 1 68032-394-90 90 TABLET In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		12/14/2009	06/30/2012

Labeler - River's Edge Pharmaceuticals, LLC (133879135)

Revised: 04/2011River's Edge Pharmaceuticals, LLC

More RE-Nata 29 OB Prenatal Vitamin Tablets resources

• RE-Nata 29 OB Prenatal Vitamin Tablets Use in Pregnancy & Breastfeeding
• Drug Images
• RE-Nata 29 OB Prenatal Vitamin Tablets Drug Interactions
• RE-Nata 29 OB Prenatal Vitamin Tablets Support Group
• 21 Reviews for RE-Nata 29 OB Prenatal Vitamins - Add your own review/rating

Compare RE-Nata 29 OB Prenatal Vitamin Tablets with other medications

• Vitamin/Mineral Supplementation during Pregnancy/Lactation

Malveol

Malveol may be available in the countries listed below.

Ingredient matches for Malveol

Salicylic Acid

Salicylic Acid is reported as an ingredient of Malveol in the following countries:

• Switzerland

International Drug Name Search

Benicar

Benicar is a brand name of olmesartan, approved by the FDA in the following formulation(s):

BENICAR (olmesartan medoxomil - tablet; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: April 25, 2002
  
  Strength(s): 20MG, 40MG ^[RLD], 5MG
  

Has a generic version of Benicar been approved?

No. There is currently no therapeutically equivalent version of Benicar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benicar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
  Patent 5,616,599
  Issued: April 1, 1997
  Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
  Assignee(s): Sankyo Company, Limited
  Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
  
  Patent expiration dates:
  
  
  • April 25, 2016
    
    ✓ 
    Patent use: USE AS AN ANTIHYPERTENSIVE AGENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 25, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition
  Patent 6,878,703
  Issued: April 12, 2005
  Inventor(s): Sada; Toshio & Mizuno; Makoto
  Assignee(s): Sankyo Company, Limited
  A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
  
  Patent expiration dates:
  
  
  • November 19, 2021
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • May 19, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 4, 2013 - NEW PATIENT POPULATION
  
  
  • August 4, 2013 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Benicar Consumer Information (Drugs.com)
• Benicar Consumer Information (Wolters Kluwer)
• Benicar Consumer Information (Cerner Multum)
• Benicar Advanced Consumer Information (Micromedex)
• Olmesartan Consumer Information (Wolters Kluwer)
• Olmesartan Consumer Information (Cerner Multum)
• Olmesartan Advanced Consumer Information (Micromedex)
• Olmesartan medoxomil Advanced Consumer Information (Micromedex)
• Olmesartan Medoxomil AHFS DI Monographs (ASHP)

Omizac

Omizac may be available in the countries listed below.

Ingredient matches for Omizac

Omeprazole

Omeprazole is reported as an ingredient of Omizac in the following countries:

• Ethiopia


• India


• Lithuania


• Russian Federation


• Vietnam

International Drug Name Search